Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022
Heidelberg Pharma AG announced today that it will present preclinical data on its proprietary Amanitin-based ATAC® technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting. The meeting will take place in New Orleans, Louisiana, USA, from 8th – 13th April 2022.
Details of the poster presentation:
Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models